Reducing neutrophil elastase-induced lung injury.
The first trial of alpha1-proteinase inhibitor therapy for the prevention of chronic lung disease of prematurity was recently completed. Receipt of four intravenous doses of the medication was associated with a trend towards a reduction in respiratory morbidity. A dose-ranging trial is in progress.
D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D016022:Case-Control Studies; D015331:Cohort Studies; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D019102:Infant, Very Low Birth Weight; D007275:Injections, Intravenous; D019272:Leukocyte Elastase / Q000037:antagonists & inhibitors*; D016015:Logistic Models; D016017:Odds Ratio; D010865:Pilot Projects; D010919:Placebos; D011446:Prospective Studies; D015842:Serine Proteinase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D014361:Trypsin Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000008:administration & dosage / Q000627:therapeutic use*